BioProgress buys US-based airPharma for £4.2m; raises £6.15m in share placing

The speciality pharmaceutical and healthcare company BioProgress plc (BPRG.L) said today that will acquire the pharmaceutical trading assets of airPharma LLC, a US based maker of respiratory products, for £4.2m.

This acquisition will enable it to leverage its technologies into own branded products in the US. BioProgress said it also benefits from being able to use airPharma’s sales and distribution arrangements with US distribution companies Cardinal, McKesson and AmerisourceBergen.

CEO Richard Trevillion (pictured) said: “The synergies both in terms of our existing branded products and new line extensions should be capable of significant revenue generation in 2007. We will be utilising our TabWrap, EntWrap and Soluleaves systems almost immediately to add value to these products creating new launch opportunities early in the New Year.

“The acquisition of the airPharma brands continues BioProgress’ successful acquisition strategy”.

airPharma assets comprise 20 brands such as Ah-Chew and SINUvent, ten of which are marketed and will be re-branded under Dexo, BioProgress’ US division. The products portfolio is established and mature, consisting of products for the treatment of chronic respiratory conditions such as asthma and rhinitis and fits well with BioProgress’ European range of products such as Collunovar. The products acquired are mainly community prescription medicines.

Sales of the airPharma brands are expected to be about $4.2m in 2006.

$4m (£2.1m) of the acquisition cost will be paid in cash. The rest will in sterling denominated BioProgress ordinary shares in two tranches. The first of $2m will be issued after 31 December based on the last closing bid price on the immediately preceding trading day. The second tranche of $2m will be issued next March, provided gross sales for 2006 are at least $3.3m.

BioProgress also announced a placing of 12.3m new ordinary shares with new and existing institutional investors, representing around 8.7% of existing share capital, at 50p each (an 11.3% discount to the mid-market closing share price over the fifteen trading days prior to the announcement). The placing was oversubscribed.

New Technology

BioProgress also announced the launch of a new enabling technology, SoluPol, a method for delivering liquid dosages.

Liquid medicines can offer an alternative to the traditional solid dosage forms but taste issues have to be overcome. SoluPol has the ability to taste mask, enhance stability and create novel small volume buccal liquids, the Cambridge-headquartered company said. These liquids can also have a muco-adhesive or muco-protective effect within the mouth.

BioProgress said it is in talks with pharmaceutical firms to develop SoluPol products. There has been a deal in principle for the development and licensing of a specific product using SoluPol with a division of Zentiva AS, a pharma based in the Czech Republic and part owned by Sanofi Aventis, for the CEE and CIS regions. Talks continue with licensing partners in Western Europe and North America for both prescription and OTC rights to this product.

Chief Development Officer Steve Martin said that with its aim of delivering medicines better, “we are able to offer the patient choice in how they take their daily medicines”.

SoluPol is complementary to its Soluleaves and TabWrap enabling technologies with the ability to offer higher doses of active drug, but in a patient-friendly manner.

The group’s share price slipped 4% to 60.50p on the news, valuing the company at around £85m. The share price has almost doubled since August.

30th October 2006

Previous articles
ANT has good revenue gains in ’09; losses narrow: profitable in 2H
Silicon Fen icon Gerald Avison moves upstairs at TTP Group
Light shining brightly for re-focussed Dialight
Phytopharm halves after-tax loss; assessing ‘strategic options’
Alizyme narrows ’08 loss as R&D spend slows
BioProgress buys OTC Melbrosin for £23.6m; to raise £4.9m in share placing, change name to Meldex
Traditional Chinese Medicine research JV sets up in the Babraham Bioincubator; first in UK
Plastic Logic opens new plant in Dresden; to deliver 1st consumer products early ‘09
Briefs: OpenCloud raises $10m in 2nd round funding; Antitope signs research deal with Fusion Antibodies
ARM to show ‘stunning mobile Internet devices’; 1st sight of Google’s Android mobile phone?
Subscribe

 

Managed Hosting by NTT Managed Hosting
SEO London by IdeaTaxi.com
Corporate profiles

 • Cambridge Capital Group


Straun McDougal
Director


Cambridge Capital Group is a syndicate of 35 private investors, based in UK and abroad, all of whom are successful entrepreneurs in their respective fields. Although it has some Cambridge based members, our main interest is to enable private individuals from outside the area to invest in young, exciting

[Cambridge Capital Group's profile]


Top20 Index




Currently: 161